Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Patient with amyotrophic lateral sclerosis (ALS) having anti-NRIP autoantibody showed titer-dependent detrimental Effects. Plasmapheresis might benefit this subgroup of patients via removal of anti-NRIP autoantibody

Who May Be Eligible (Plain English)

Who May Qualify: 1. Patients with amyotrophic lateral sclerosis (ALS) at the age more than 20 years and having plasma anti-NRIP autoantibody. 2. Agree to receive plasmapheresis intervention. 3. Agree to participate in the trial and receive serial examinations and follow up. Who Should NOT Join This Trial: 1. Patients without plasma anti-NRIP autoantibody. 2. Patients requiring permanent ventilator support for ALS progression. 3. Not able to receive plasmapheresis or trial-related examinations. 4. Under pregnancy. 5. Blood fibrinogen level less than 50 mg/dl. 6. Specific ALS subtypes, including primary lateral sclerosis, progressive muscular atrophy, flail arm syndrome, or flail leg syndrome. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: 1. Patients with amyotrophic lateral sclerosis (ALS) at the age more than 20 years and having plasma anti-NRIP autoantibody. 2. Agree to receive plasmapheresis intervention. 3. Agree to participate in the trial and receive serial examinations and follow up. Exclusion Criteria: 1. Patients without plasma anti-NRIP autoantibody. 2. Patients requiring permanent ventilator support for ALS progression. 3. Not able to receive plasmapheresis or trial-related examinations. 4. Under pregnancy. 5. Blood fibrinogen level less than 50 mg/dl. 6. Specific ALS subtypes, including primary lateral sclerosis, progressive muscular atrophy, flail arm syndrome, or flail leg syndrome.

Treatments Being Tested

PROCEDURE

Plasmapheresis

Regular plasmapheresis to remove anti-NRIP autoantibody

Locations (1)

National Taiwan University Hospital
Taipei, Taiwan